Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
Clinical trial NCT06890182 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06890182
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2026-12-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.